Functionalized  ||| S:0 E:15 ||| NNP
tetrahydro-1H-pyrido ||| S:15 E:35 ||| NNP
[ ||| S:35 E:36 ||| -LRB-
4,3-b ||| S:36 E:41 ||| NNP
] ||| S:41 E:42 ||| -RRB-
indoles ||| S:42 E:49 ||| NN
:  ||| S:49 E:51 ||| :
a  ||| S:51 E:53 ||| DT
novel  ||| S:53 E:59 ||| NN
chemotype  ||| S:59 E:69 ||| NN
with  ||| S:69 E:74 ||| IN
Sirtuin  ||| S:74 E:82 ||| NNP
2  ||| S:82 E:84 ||| CD
inhibitory  ||| S:84 E:95 ||| JJ
activity  ||| S:95 E:104 ||| NN
Sirtuins  ||| S:104 E:113 ||| NNS
are  ||| S:113 E:117 ||| VBP
protein  ||| S:117 E:125 ||| JJ
deacylases  ||| S:125 E:136 ||| NN
with  ||| S:136 E:141 ||| IN
regulatory  ||| S:141 E:152 ||| JJ
roles  ||| S:152 E:158 ||| NNS
in  ||| S:158 E:161 ||| IN
metabolism  ||| S:161 E:172 ||| NN
and  ||| S:172 E:176 ||| CC
stress  ||| S:176 E:183 ||| NN
response ||| S:183 E:191 ||| NN
.  ||| S:191 E:193 ||| .
Functionalized  ||| S:193 E:208 ||| NNP
tetrahydro-1H-pyrido ||| S:208 E:228 ||| NNP
[ ||| S:228 E:229 ||| -LRB-
4,3-b ||| S:229 E:234 ||| NNP
] ||| S:234 E:235 ||| -RRB-
indoles  ||| S:235 E:243 ||| NN
were  ||| S:243 E:248 ||| VBD
identified  ||| S:248 E:259 ||| VBN
as  ||| S:259 E:262 ||| IN
preferential  ||| S:262 E:275 ||| JJ
sirtuin  ||| S:275 E:283 ||| NN
2  ||| S:283 E:285 ||| CD
inhibitors ||| S:285 E:295 ||| NN
,  ||| S:295 E:297 ||| ,
with  ||| S:297 E:302 ||| IN
in vitro  ||| S:302 E:311 ||| CD
inhibitory  ||| S:311 E:322 ||| JJ
potencies  ||| S:322 E:332 ||| NN
in  ||| S:332 E:335 ||| IN
the  ||| S:335 E:339 ||| DT
low  ||| S:339 E:343 ||| JJ
micromolar  ||| S:343 E:354 ||| JJ
concentrations  ||| S:354 E:369 ||| NNS
( ||| S:369 E:370 ||| -LRB-
IC50  ||| S:370 E:375 ||| NNP
3-4 μM ||| S:375 E:381 ||| NNP
)  ||| S:381 E:383 ||| -RRB-
for  ||| S:383 E:387 ||| IN
the  ||| S:387 E:391 ||| DT
more  ||| S:391 E:396 ||| RBR
promising  ||| S:396 E:406 ||| JJ
candidates ||| S:406 E:416 ||| NNS
.  ||| S:416 E:418 ||| .
The  ||| S:418 E:422 ||| DT
functional  ||| S:422 E:433 ||| JJ
relevance  ||| S:433 E:443 ||| NN
of  ||| S:443 E:446 ||| IN
sirtuin  ||| S:446 E:454 ||| JJ
inhibition  ||| S:454 E:465 ||| NN
was  ||| S:465 E:469 ||| VBD
corroborated  ||| S:469 E:482 ||| VBN
in  ||| S:482 E:485 ||| IN
western  ||| S:485 E:493 ||| JJ
blots  ||| S:493 E:499 ||| NN
that  ||| S:499 E:504 ||| WDT
showed  ||| S:504 E:511 ||| VBD
hyperacetylation  ||| S:511 E:528 ||| VBN
of  ||| S:528 E:531 ||| IN
p53  ||| S:531 E:535 ||| NN
and  ||| S:535 E:539 ||| CC
α-tubulin  ||| S:539 E:549 ||| JJ
in  ||| S:549 E:552 ||| IN
treated  ||| S:552 E:560 ||| JJ
HepG2  ||| S:560 E:566 ||| NN
and  ||| S:566 E:570 ||| CC
MDA-MB-231  ||| S:570 E:581 ||| CD
cells ||| S:581 E:586 ||| NNS
.  ||| S:586 E:588 ||| .
Molecular  ||| S:588 E:598 ||| JJ
docking  ||| S:598 E:606 ||| NN
showed  ||| S:606 E:613 ||| VBD
that  ||| S:613 E:618 ||| IN
the  ||| S:618 E:622 ||| DT
tetrahydropyridoindole  ||| S:622 E:645 ||| JJ
scaffold  ||| S:645 E:654 ||| NN
was  ||| S:654 E:658 ||| VBD
positioned  ||| S:658 E:669 ||| VBN
in  ||| S:669 E:672 ||| IN
the  ||| S:672 E:676 ||| DT
NAD + pocket  ||| S:676 E:689 ||| NNP
and  ||| S:689 E:693 ||| CC
the  ||| S:693 E:697 ||| DT
acetylated  ||| S:697 E:708 ||| JJ
substrate  ||| S:708 E:718 ||| JJ
channel  ||| S:718 E:726 ||| NN
of  ||| S:726 E:729 ||| IN
the  ||| S:729 E:733 ||| DT
sirtuin  ||| S:733 E:741 ||| JJ
2  ||| S:741 E:743 ||| CD
protein  ||| S:743 E:751 ||| NN
by  ||| S:751 E:754 ||| IN
van  ||| S:754 E:758 ||| NNP
der  ||| S:758 E:762 ||| FW
Waals ||| S:762 E:767 ||| FW
/ ||| S:767 E:768 ||| FW
hydrophobic ||| S:768 E:779 ||| FW
,  ||| S:779 E:781 ||| ,
H  ||| S:781 E:783 ||| NNP
bonding  ||| S:783 E:791 ||| NN
and  ||| S:791 E:795 ||| CC
stacking  ||| S:795 E:804 ||| VBG
interactions ||| S:804 E:816 ||| NNS
.  ||| S:816 E:818 ||| .
Functionalized  ||| S:818 E:833 ||| JJ
tetrahydropyridoindoles  ||| S:833 E:857 ||| NNS
represent  ||| S:857 E:867 ||| VBP
a  ||| S:867 E:869 ||| DT
novel  ||| S:869 E:875 ||| NN
class  ||| S:875 E:881 ||| NN
of  ||| S:881 E:884 ||| IN
sirtuin  ||| S:884 E:892 ||| CD
2  ||| S:892 E:894 ||| CD
inhibitors  ||| S:894 E:905 ||| NNS
that  ||| S:905 E:910 ||| WDT
could  ||| S:910 E:916 ||| MD
be  ||| S:916 E:919 ||| VB
further  ||| S:919 E:927 ||| JJ
explored  ||| S:927 E:936 ||| NN
for  ||| S:936 E:940 ||| IN
its  ||| S:940 E:944 ||| PRP$
therapeutic  ||| S:944 E:956 ||| JJ
potential ||| S:956 E:965 ||| NN
.  ||| S:965 E:967 ||| .
